ID   RN5A_HUMAN              Reviewed;         741 AA.
AC   Q05823; Q5W0L2; Q6AI46;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   12-OCT-2022, entry version 203.
DE   RecName: Full=2-5A-dependent ribonuclease;
DE            Short=2-5A-dependent RNase;
DE            EC=3.1.26.-;
DE   AltName: Full=Ribonuclease 4;
DE   AltName: Full=Ribonuclease L;
DE            Short=RNase L;
GN   Name=RNASEL; Synonyms=RNS4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS OF LYS-240 AND LYS-274.
RC   TISSUE=Kidney;
RX   PubMed=7680958; DOI=10.1016/0092-8674(93)90403-d;
RA   Zhou A., Hassel B.A., Silverman R.H.;
RT   "Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator
RT   of interferon action.";
RL   Cell 72:753-765(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=11063255; DOI=10.1007/s003350010194;
RA   Zhou A., Nie H., Silverman R.H.;
RT   "Analysis and origins of the human and mouse RNase L genes: mediators of
RT   interferon action.";
RL   Mamm. Genome 11:989-992(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon carcinoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHARACTERIZATION OF RNASEL ACTIVITY.
RX   PubMed=7514601; DOI=10.1016/s0021-9258(17)36767-4;
RA   Dong B., Xu L., Zhou A., Hassel B.A., Lee X., Torrence P.F.,
RA   Silverman R.H.;
RT   "Intrinsic molecular activities of the interferon-induced 2-5A-dependent
RT   RNase.";
RL   J. Biol. Chem. 269:14153-14158(1994).
RN   [8]
RP   INTERACTION WITH ABCE1.
RX   PubMed=7539425; DOI=10.1074/jbc.270.22.13308;
RA   Bisbal C., Martinand C., Silhol M., Lebleu B., Salehzada T.;
RT   "Cloning and characterization of a RNase L inhibitor. A new component of
RT   the interferon-regulated 2-5A pathway.";
RL   J. Biol. Chem. 270:13308-13317(1995).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11585831; DOI=10.1074/jbc.m107482200;
RA   Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., Salehzada T.;
RT   "The 2-5A/RNase L/RNase L inhibitor (RNI) pathway regulates mitochondrial
RT   mRNAs stability in interferon alpha-treated H9 cells.";
RL   J. Biol. Chem. 276:48473-48482(2001).
RN   [10]
RP   ERRATUM OF PUBMED:11585831.
RA   Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., Salehzada T.;
RL   J. Biol. Chem. 277:13354-13354(2002).
RN   [11]
RP   REVIEW.
RX   PubMed=9856285; DOI=10.1016/s0753-3322(99)80006-7;
RA   Castelli J., Wood K.A., Youle R.J.;
RT   "The 2-5A system in viral infection and apoptosis.";
RL   Biomed. Pharmacother. 52:386-390(1998).
RN   [12]
RP   MUTAGENESIS OF LYS-392.
RX   PubMed=9862963; DOI=10.1093/nar/27.2.439;
RA   Dong B., Silverman R.H.;
RT   "Alternative function of a protein kinase homology domain in 2', 5'-
RT   oligoadenylate dependent RNase L.";
RL   Nucleic Acids Res. 27:439-445(1999).
RN   [13]
RP   MUTAGENESIS OF HIS-583; PRO-584; TRP-632; ASP-661; ARG-667 AND HIS-672.
RX   PubMed=11333017; DOI=10.1017/s1355838201002230;
RA   Dong B., Niwa M., Walter P., Silverman R.H.;
RT   "Basis for regulated RNA cleavage by functional analysis of RNase L and
RT   Ire1p.";
RL   RNA 7:361-373(2001).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-684, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   FUNCTION.
RX   PubMed=26263979; DOI=10.3390/ijms160817611;
RA   Siddiqui M.A., Mukherjee S., Manivannan P., Malathi K.;
RT   "RNase L cleavage products promote switch from autophagy to apoptosis by
RT   caspase-mediated cleavage of beclin-1.";
RL   Int. J. Mol. Sci. 16:17611-17636(2015).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-305 IN COMPLEX WITH THE
RP   ACTIVATOR 2-5A.
RX   PubMed=15385955; DOI=10.1038/sj.emboj.7600420;
RA   Tanaka N., Nakanishi M., Kusakabe Y., Goto Y., Kitade Y., Nakamura K.T.;
RT   "Structural basis for recognition of 2',5'-linked oligoadenylates by human
RT   ribonuclease L.";
RL   EMBO J. 23:3929-3938(2004).
RN   [17]
RP   VARIANTS SER-59; PHE-406; GLN-462 AND GLU-541.
RX   PubMed=11941539; DOI=10.1086/340450;
RA   Roekman A., Ikonen T., Seppaelae E.H., Nupponen N., Autio V., Mononen N.,
RA   Bailey-Wilson J., Trent J., Carpten J., Matikainen M.P., Koivisto P.A.,
RA   Tammela T.L.J., Kallioniemi O.-P., Schleutker J.;
RT   "Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in
RT   patients and families with prostate cancer.";
RL   Am. J. Hum. Genet. 70:1299-1304(2002).
RN   [18]
RP   VARIANTS SER-59; GLN-462 AND GLU-541.
RX   PubMed=11799394; DOI=10.1038/ng823;
RA   Carpten J., Nupponen N., Isaacs S., Sood R., Robbins C., Xu J., Faruque M.,
RA   Moses T., Ewing C., Gillanders E., Hu P., Bujnovszky P., Makalowska I.,
RA   Baffoe-Bonnie A., Faith D., Smith J., Stephan D., Wiley K., Brownstein M.,
RA   Gildea D., Kelly B., Jenkins R., Hostetter G., Matikainen M.,
RA   Schleutker J., Klinger K., Connors T., Xiang Y., Wang Z., De Marzo A.,
RA   Papadopoulos N., Kallioniemi O.-P., Burk R., Meyers D., Groenberg H.,
RA   Meltzer P., Silverman R., Bailey-Wilson J., Walsh P., Isaacs W., Trent J.;
RT   "Germline mutations in the ribonuclease L gene in families showing linkage
RT   with HPC1.";
RL   Nat. Genet. 30:181-184(2002).
RN   [19]
RP   CHARACTERIZATION OF VARIANTS GLN-462 AND GLU-541.
RX   PubMed=12415269; DOI=10.1038/ng1021;
RA   Casey G., Neville P.J., Plummer S.J., Xiang Y., Krumroy L.M., Klein E.A.,
RA   Catalona W.J., Nupponen N., Carpten J.D., Trent J.M., Silverman R.H.,
RA   Witte J.S.;
RT   "RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer
RT   cases.";
RL   Nat. Genet. 32:581-583(2002).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-97; THR-289; GLN-462; GLU-541 AND
RP   HIS-592.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Endoribonuclease that functions in the interferon (IFN)
CC       antiviral response. In INF treated and virus infected cells, RNASEL
CC       probably mediates its antiviral effects through a combination of direct
CC       cleavage of single-stranded viral RNAs, inhibition of protein synthesis
CC       through the degradation of rRNA, induction of apoptosis, and induction
CC       of other antiviral genes. RNASEL mediated apoptosis is the result of a
CC       JNK-dependent stress-response pathway leading to cytochrome c release
CC       from mitochondria and caspase-dependent apoptosis. Therefore,
CC       activation of RNASEL could lead to elimination of virus infected cells
CC       under some circumstances. In the crosstalk between autophagy and
CC       apoptosis proposed to induce autophagy as an early stress response to
CC       small double-stranded RNA and at later stages of prolonged stress to
CC       activate caspase-dependent proteolytic cleavage of BECN1 to terminate
CC       autophagy and promote apoptosis (PubMed:26263979). Might play a central
CC       role in the regulation of mRNA turnover (PubMed:11585831). Cleaves 3'
CC       of UpNp dimers, with preference for UU and UA sequences, to sets of
CC       discrete products ranging from between 4 and 22 nucleotides in length.
CC       {ECO:0000269|PubMed:11585831, ECO:0000269|PubMed:26263979}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC       Note=Manganese or magnesium. Required for optimal RNA cleavage rates.;
CC   -!- ACTIVITY REGULATION: After binding to 2-5A (5'-phosphorylated 2',5'-
CC       linked oligoadenylates) the homodimerization and subsequent activation
CC       occurs. Inhibited by RNASEL inhibitor ABCE1/RLI, a cytoplasmic member
CC       of the ATP-binding cassette (ABC) transporter family.
CC   -!- SUBUNIT: Monomer (inactive form) or homodimer. Interacts with ABCE1;
CC       this interaction inhibits the RNASEL. {ECO:0000269|PubMed:15385955,
CC       ECO:0000269|PubMed:7539425}.
CC   -!- INTERACTION:
CC       Q05823; P46940: IQGAP1; NbExp=2; IntAct=EBI-8390477, EBI-297509;
CC       Q05823-1; Q05823-1: RNASEL; NbExp=2; IntAct=EBI-16094551, EBI-16094551;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11585831}.
CC       Mitochondrion {ECO:0000269|PubMed:11585831}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q05823-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q05823-2; Sequence=VSP_056272, VSP_056273;
CC   -!- TISSUE SPECIFICITY: Highly expressed in spleen and thymus followed by
CC       prostate, testis, uterus, small intestine, colon and peripheral blood
CC       leukocytes.
CC   -!- INDUCTION: By interferons. Virus replication in higher vertebrates is
CC       restrained by IFNs that cause cells to transcribe genes encoding
CC       antiviral proteins, such as 2'-5' oligoadenylate synthetases (OASs).
CC       oligoadenylate synthetase is stimulated by dsRNA to produce 5'-
CC       phosphorylated, 2'-5'-linked oligoadenylates (2-5A), whose function is
CC       to activate RNASEL.
CC   -!- DOMAIN: The nine ankyrin repeats also called 2-5A sensor constitute the
CC       N-terminus 2-5A binding domain.
CC   -!- DOMAIN: The protein kinase domain is predicted to be catalytically
CC       inactive. It allows the homodimerization.
CC   -!- DOMAIN: The ribonuclease domain is located in the C-terminus. A single
CC       active nuclease domain in a dimer is sufficient for ribonuclease
CC       activity (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Prostate cancer, hereditary, 1 (HPC1) [MIM:601518]: A
CC       condition associated with familial predisposition to cancer of the
CC       prostate. Most prostate cancers are adenocarcinomas that develop in the
CC       acini of the prostatic ducts. Other rare histopathologic types of
CC       prostate cancer that occur in approximately 5% of patients include
CC       small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma,
CC       transitional cell carcinoma, squamous cell carcinoma, basal cell
CC       carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell
CC       carcinoma and neuroendocrine carcinoma. {ECO:0000305|PubMed:11799394,
CC       ECO:0000305|PubMed:11941539, ECO:0000305|PubMed:12415269,
CC       ECO:0000305|PubMed:17344846}. Note=Disease susceptibility is associated
CC       with variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L10381; AAA18032.1; -; Genomic_DNA.
DR   EMBL; CR627369; CAH10468.1; -; mRNA.
DR   EMBL; AL138776; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471067; EAW91128.1; -; Genomic_DNA.
DR   EMBL; BC090934; AAH90934.1; -; mRNA.
DR   EMBL; BC114433; AAI14434.1; -; mRNA.
DR   CCDS; CCDS1347.1; -. [Q05823-1]
DR   PIR; A45771; A45771.
DR   RefSeq; NP_066956.1; NM_021133.3. [Q05823-1]
DR   PDB; 1WDY; X-ray; 1.80 A; A=21-305.
DR   PDB; 4G8K; X-ray; 2.40 A; A/B=1-337.
DR   PDB; 4G8L; X-ray; 2.80 A; A/B/C/D=1-337.
DR   PDB; 4OAU; X-ray; 2.60 A; C=21-719.
DR   PDB; 4OAV; X-ray; 2.10 A; B/D=21-719.
DR   PDBsum; 1WDY; -.
DR   PDBsum; 4G8K; -.
DR   PDBsum; 4G8L; -.
DR   PDBsum; 4OAU; -.
DR   PDBsum; 4OAV; -.
DR   AlphaFoldDB; Q05823; -.
DR   SMR; Q05823; -.
DR   BioGRID; 111969; 23.
DR   DIP; DIP-61367N; -.
DR   IntAct; Q05823; 22.
DR   MINT; Q05823; -.
DR   STRING; 9606.ENSP00000356530; -.
DR   BindingDB; Q05823; -.
DR   ChEMBL; CHEMBL3575; -.
DR   iPTMnet; Q05823; -.
DR   PhosphoSitePlus; Q05823; -.
DR   BioMuta; RNASEL; -.
DR   DMDM; 1350802; -.
DR   EPD; Q05823; -.
DR   jPOST; Q05823; -.
DR   MassIVE; Q05823; -.
DR   PaxDb; Q05823; -.
DR   PeptideAtlas; Q05823; -.
DR   PRIDE; Q05823; -.
DR   ProteomicsDB; 58353; -. [Q05823-1]
DR   ProteomicsDB; 66189; -.
DR   Antibodypedia; 1127; 217 antibodies from 27 providers.
DR   DNASU; 6041; -.
DR   Ensembl; ENST00000367559.7; ENSP00000356530.3; ENSG00000135828.11. [Q05823-1]
DR   Ensembl; ENST00000539397.1; ENSP00000440844.1; ENSG00000135828.11. [Q05823-2]
DR   GeneID; 6041; -.
DR   KEGG; hsa:6041; -.
DR   MANE-Select; ENST00000367559.7; ENSP00000356530.3; NM_021133.4; NP_066956.1.
DR   UCSC; uc001gpk.4; human. [Q05823-1]
DR   CTD; 6041; -.
DR   DisGeNET; 6041; -.
DR   GeneCards; RNASEL; -.
DR   HGNC; HGNC:10050; RNASEL.
DR   HPA; ENSG00000135828; Low tissue specificity.
DR   MalaCards; RNASEL; -.
DR   MIM; 176807; phenotype.
DR   MIM; 180435; gene.
DR   MIM; 601518; phenotype.
DR   neXtProt; NX_Q05823; -.
DR   OpenTargets; ENSG00000135828; -.
DR   Orphanet; 1331; Familial prostate cancer.
DR   PharmGKB; PA34418; -.
DR   VEuPathDB; HostDB:ENSG00000135828; -.
DR   eggNOG; KOG1027; Eukaryota.
DR   eggNOG; KOG4177; Eukaryota.
DR   GeneTree; ENSGT00940000161114; -.
DR   HOGENOM; CLU_022542_0_0_1; -.
DR   InParanoid; Q05823; -.
DR   OMA; VLYVVRK; -.
DR   OrthoDB; 222916at2759; -.
DR   PhylomeDB; Q05823; -.
DR   TreeFam; TF344032; -.
DR   BioCyc; MetaCyc:HS06069-MON; -.
DR   BRENDA; 4.6.1.19; 2681.
DR   PathwayCommons; Q05823; -.
DR   Reactome; R-HSA-8983711; OAS antiviral response.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   SignaLink; Q05823; -.
DR   SIGNOR; Q05823; -.
DR   BioGRID-ORCS; 6041; 8 hits in 1112 CRISPR screens.
DR   ChiTaRS; RNASEL; human.
DR   EvolutionaryTrace; Q05823; -.
DR   GeneWiki; Ribonuclease_L; -.
DR   GeneWiki; RNASEL; -.
DR   GenomeRNAi; 6041; -.
DR   Pharos; Q05823; Tchem.
DR   PRO; PR:Q05823; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q05823; protein.
DR   Bgee; ENSG00000135828; Expressed in amniotic fluid and 172 other tissues.
DR   Genevisible; Q05823; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0016363; C:nuclear matrix; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004521; F:endoribonuclease activity; NAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0004540; F:ribonuclease activity; IDA:ARUK-UCL.
DR   GO; GO:0043021; F:ribonucleoprotein complex binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0019843; F:rRNA binding; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0006397; P:mRNA processing; IEA:InterPro.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB.
DR   GO; GO:0046326; P:positive regulation of glucose import; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   GO; GO:0043488; P:regulation of mRNA stability; IEA:Ensembl.
DR   GO; GO:0006396; P:RNA processing; IBA:GO_Central.
DR   GO; GO:0006364; P:rRNA processing; IEA:Ensembl.
DR   CDD; cd10423; RNase_RNase-L; 1.
DR   Gene3D; 1.20.1440.180; -; 1.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR010513; KEN_dom.
DR   InterPro; IPR038357; KEN_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR042745; RNase-L_RNase.
DR   Pfam; PF12796; Ank_2; 3.
DR   Pfam; PF13857; Ank_5; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF06479; Ribonuc_2-5A; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 8.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 6.
DR   PROSITE; PS51392; KEN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ANK repeat;
KW   Antiviral defense; ATP-binding; Cytoplasm; Endonuclease; Hydrolase;
KW   Metal-binding; Mitochondrion; Nuclease; Nucleotide-binding;
KW   Reference proteome; Repeat; RNA-binding; Zinc; Zinc-finger.
FT   CHAIN           1..741
FT                   /note="2-5A-dependent ribonuclease"
FT                   /id="PRO_0000067051"
FT   REPEAT          24..53
FT                   /note="ANK 1"
FT   REPEAT          58..87
FT                   /note="ANK 2"
FT   REPEAT          91..120
FT                   /note="ANK 3"
FT   REPEAT          124..153
FT                   /note="ANK 4"
FT   REPEAT          167..197
FT                   /note="ANK 5"
FT   REPEAT          201..234
FT                   /note="ANK 6"
FT   REPEAT          238..268
FT                   /note="ANK 7"
FT   REPEAT          272..301
FT                   /note="ANK 8"
FT   REPEAT          303..329
FT                   /note="ANK 9"
FT   DOMAIN          365..586
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          589..723
FT                   /note="KEN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00725"
FT   ZN_FING         395..444
FT                   /note="C6-type; atypical"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          229..242
FT                   /note="2-5A binding (P-loop) 1"
FT   REGION          253..275
FT                   /note="2-5A binding (P-loop) 2"
FT   REGION          715..741
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         684
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   VAR_SEQ         636..652
FT                   /note="INECVMKKMNKFYEKRG -> MSKLRHRQIIFPTTQNQ (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_056272"
FT   VAR_SEQ         653..741
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_056273"
FT   VARIANT         59
FT                   /note="G -> S (in dbSNP:rs151296858)"
FT                   /evidence="ECO:0000269|PubMed:11799394,
FT                   ECO:0000269|PubMed:11941539"
FT                   /id="VAR_013509"
FT   VARIANT         97
FT                   /note="I -> L (in dbSNP:rs56250729)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042358"
FT   VARIANT         289
FT                   /note="A -> T (in dbSNP:rs35553278)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042359"
FT   VARIANT         406
FT                   /note="S -> F (in dbSNP:rs145787003)"
FT                   /evidence="ECO:0000269|PubMed:11941539"
FT                   /id="VAR_013510"
FT   VARIANT         462
FT                   /note="R -> Q (risk factor for prostate cancer; reduced
FT                   enzymatic activity; dbSNP:rs486907)"
FT                   /evidence="ECO:0000269|PubMed:11799394,
FT                   ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_012056"
FT   VARIANT         541
FT                   /note="D -> E (no change in enzymatic activity;
FT                   dbSNP:rs627928)"
FT                   /evidence="ECO:0000269|PubMed:11799394,
FT                   ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_012057"
FT   VARIANT         592
FT                   /note="R -> H (in dbSNP:rs35896902)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042360"
FT   MUTAGEN         240
FT                   /note="K->N: Reduced 2-5A binding activity; almost complete
FT                   loss of 2-5A binding activity; when associated with N-274."
FT                   /evidence="ECO:0000269|PubMed:7680958"
FT   MUTAGEN         274
FT                   /note="K->N: Reduced 2-5A binding activity; almost complete
FT                   loss of 2-5A binding activity; when associated with N-240."
FT                   /evidence="ECO:0000269|PubMed:7680958"
FT   MUTAGEN         392
FT                   /note="K->R: Complete loss of enzymatic activity and enzyme
FT                   dimerization. No change in binding to 2-5A and RNA."
FT                   /evidence="ECO:0000269|PubMed:9862963"
FT   MUTAGEN         583
FT                   /note="H->A: No change in enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:11333017"
FT   MUTAGEN         584
FT                   /note="P->A: No change in enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:11333017"
FT   MUTAGEN         632
FT                   /note="W->A: No change in enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:11333017"
FT   MUTAGEN         661
FT                   /note="D->A: Complete loss of enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:11333017"
FT   MUTAGEN         667
FT                   /note="R->A: Complete loss of enzymatic activity. No change
FT                   in 2-5A binding and enzyme dimerization."
FT                   /evidence="ECO:0000269|PubMed:11333017"
FT   MUTAGEN         672
FT                   /note="H->A: Complete loss of enzymatic activity. No change
FT                   in 2-5A binding activity and enzyme dimerization."
FT                   /evidence="ECO:0000269|PubMed:11333017"
FT   HELIX           22..34
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           38..46
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   TURN            56..58
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           62..68
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           72..80
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           95..102
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           105..113
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           128..134
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           138..146
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           159..163
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           171..178
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           181..189
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           205..211
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   TURN            215..217
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           218..227
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           237..239
FT                   /evidence="ECO:0007829|PDB:4G8K"
FT   HELIX           242..248
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           252..260
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   STRAND          261..263
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           276..282
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   HELIX           286..295
FT                   /evidence="ECO:0007829|PDB:1WDY"
FT   STRAND          301..303
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           304..310
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           314..322
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   STRAND          341..344
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           345..352
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   STRAND          361..363
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           367..369
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   STRAND          370..374
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   STRAND          377..395
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           399..409
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   STRAND          420..425
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   STRAND          427..435
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   STRAND          438..440
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           441..445
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           459..477
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           488..490
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   STRAND          491..493
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   STRAND          495..497
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   STRAND          499..501
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           514..532
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   TURN            533..535
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           539..544
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           547..551
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           557..567
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           576..580
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           584..586
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           589..600
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           603..606
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           613..618
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   TURN            628..631
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           632..634
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           638..645
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           646..648
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   TURN            649..652
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           659..672
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           681..685
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           688..695
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           699..707
FT                   /evidence="ECO:0007829|PDB:4OAV"
FT   HELIX           711..715
FT                   /evidence="ECO:0007829|PDB:4OAV"
SQ   SEQUENCE   741 AA;  83533 MW;  91385EA307E3CE1D CRC64;
     MESRDHNNPQ EGPTSSSGRR AAVEDNHLLI KAVQNEDVDL VQQLLEGGAN VNFQEEEGGW
     TPLHNAVQMS REDIVELLLR HGADPVLRKK NGATPFILAA IAGSVKLLKL FLSKGADVNE
     CDFYGFTAFM EAAVYGKVKA LKFLYKRGAN VNLRRKTKED QERLRKGGAT ALMDAAEKGH
     VEVLKILLDE MGADVNACDN MGRNALIHAL LSSDDSDVEA ITHLLLDHGA DVNVRGERGK
     TPLILAVEKK HLGLVQRLLE QEHIEINDTD SDGKTALLLA VELKLKKIAE LLCKRGASTD
     CGDLVMTARR NYDHSLVKVL LSHGAKEDFH PPAEDWKPQS SHWGAALKDL HRIYRPMIGK
     LKFFIDEKYK IADTSEGGIY LGFYEKQEVA VKTFCEGSPR AQREVSCLQS SRENSHLVTF
     YGSESHRGHL FVCVTLCEQT LEACLDVHRG EDVENEEDEF ARNVLSSIFK AVQELHLSCG
     YTHQDLQPQN ILIDSKKAAH LADFDKSIKW AGDPQEVKRD LEDLGRLVLY VVKKGSISFE
     DLKAQSNEEV VQLSPDEETK DLIHRLFHPG EHVRDCLSDL LGHPFFWTWE SRYRTLRNVG
     NESDIKTRKS ESEILRLLQP GPSEHSKSFD KWTTKINECV MKKMNKFYEK RGNFYQNTVG
     DLLKFIRNLG EHIDEEKHKK MKLKIGDPSL YFQKTFPDLV IYVYTKLQNT EYRKHFPQTH
     SPNKPQCDGA GGASGLASPG C
//
